TRADJENTA
Clinical safety rating: caution
Comprehensive clinical and safety monograph for TRADJENTA (TRADJENTA).
Linagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor. It slows the inactivation of incretin hormones GLP-1 and GIP, increasing their levels, which stimulates insulin secretion and suppresses glucagon release in a glucose-dependent manner.
| Metabolism | Linagliptin is minimally metabolized via cytochrome P450 isozymes (CYP3A4 and CYP2C8) and eliminated largely unchanged in feces (80%) and urine (5%). |
| Excretion | Approximately 85% of the dose is excreted in feces (mostly as unchanged parent drug) and about 5% in urine (largely as metabolites). Biliary excretion accounts for the majority of fecal elimination. |
| Half-life | Terminal elimination half-life is approximately 12.5 hours at steady state, consistent with once-daily dosing and supporting 24-hour DPP-4 inhibition. |
| Protein binding | Approximately 80–90% bound to plasma proteins, primarily to albumin. |
| Volume of Distribution | Volume of distribution at steady state is about 8.5 L (approx. 0.12 L/kg for a 70 kg individual), indicating limited extravascular distribution and predominantly plasma and interstitial fluid compartment. |
| Bioavailability | Oral bioavailability is approximately 30% due to incomplete absorption and first-pass metabolism. Food does not significantly alter bioavailability. |
| Onset of Action | Orally: DPP-4 inhibition is near-maximal (≥80%) within 1–2 hours after a single oral dose, but peak glucose-lowering effect may take up to 2–4 weeks of daily dosing due to HbA1c reduction kinetics. |
| Duration of Action | Once-daily dosing provides >80% DPP-4 inhibition over 24 hours, allowing for sustained glycemic control with no appreciable loss of effect over the dosing interval. |
5 mg orally once daily.
| Dosage form | TABLET |
| Renal impairment | No dose adjustment required for GFR >=30 mL/min/1.73 m². Not recommended for GFR <30 mL/min/1.73 m². |
| Liver impairment | No dose adjustment required for mild to moderate hepatic impairment (Child-Pugh A or B). Not recommended for severe hepatic impairment (Child-Pugh C). |
| Pediatric use | Safety and efficacy not established in pediatric patients. |
| Geriatric use | No specific dose adjustment required; consider renal function and potential for volume depletion. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for TRADJENTA (TRADJENTA).
| Breastfeeding | Not known if excreted in human milk; caution advised. M/P ratio not established. |
| Teratogenic Risk | Pregnancy Category B. Animal studies show no fetal harm; no adequate human studies in pregnant women. Risk not ruled out; use only if clearly needed. |
| Fetal Monitoring | Monitor blood glucose, HbA1c, and renal function periodically. |
■ FDA Black Box Warning
None
| Serious Effects |
["History of serious hypersensitivity reaction to linagliptin or any excipient","Type 1 diabetes mellitus","Diabetic ketoacidosis"]
| Precautions | ["Pancreatitis: Cases reported; monitor for symptoms.","Hypoglycemia: Risk increased when used with insulin secretagogues or insulin.","Hypersensitivity reactions: Serious allergic reactions reported.","Acute renal failure: Cases reported; monitor renal function.","Bullous pemphigoid: Reports; discontinue if suspected.","Arthralgia: Severe joint pain reported.","Heart failure: Consider risk factors; monitor for symptoms."] |
Loading safety data…
| Fertility Effects | No significant effects on fertility observed in animal studies. |